http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-016349-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2b9dc89cc4ba060cc73bbf0c90bbb78 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-618 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 1998-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-016349-A1 |
| titleOfInvention | PHARMACEUTICAL COMBINATION OF A THIAZOLIDINDIONA, AN INSULIN SECRETAGOG AND AN ANTIHIPERGLUCEMIANTE AGENT OF BIGUADINA, AND USE OF THEM IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED |
| abstract | Use of an insulin sensitizer, insulin secretagogue and an anti-hyperglycemic agent of the biguanide type for the preparation of a medicamentoutil for the treatment of diabetes mellitus and the conditions associated with diabetes mellitus in a mammal, which comprises a notoxic and pharmaceutically acceptable effective amount from an insulin sensitizer, an insulin secretagogue and an antihyperglycemic agent of the biguanide type, to a mammal that needs the same, in addition, a pharmaceutical composition comprising the active ingredients mentioned above is described. An appropriate insulin sensitizer is an insulin sensitizer of the thiazolidinedione type. An appropriate insulin sensitizer of the detiazolidinedione type is 5- [4- [2- (N-methyl-11- (2-pyridyl) amine)) -ethoxy] benzyl] thiazolidine-2,4-dione. Other appropriate insulin sensitizers of tipothiazolidinedione include: (+) - 5 - [[4 - [(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl ) -methoxy] phenyl] methyl-2,4-thiazolidinedione (or troglitazone), 5- [4 - [(1-methyl-cyclohexyl) methoxy] benzyl] thiazolidine-2,4-dione (or ciglitazone), 5- [ 4- [2- (5-ethyl-pyridin-2-yl) ethoxy] benzyl] thiazolidine-2,4-dione (opioglitazone) or 5 - [(2-benzyl-2,3-dihydro-benzopyran) -5- ilmethyl) thiazolidine-2,4-dione (or englitazone). Appropriate insulin secretagogues include sulfonylureas. Appropriate sulfonylureas include glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide. Additional sulphonylureas include acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glycopiamide and glycylamide. Additional appropriate insulin secretagogues include repaglinide. An antihyperglycemic agent of the appropriate biguanide type is metformin, buformin ofenformin, especially metformin. |
| priorityDate | 1997-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 160.